Bullfrog AI (BFRG) Competitors $1.90 +0.19 (+11.11%) Closing price 04:00 PM EasternExtended Trading$1.90 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRG vs. CTOR, ASRT, TELO, VHAQ, IKNA, SKYE, ICCC, MCRB, ACHL, and ABOSShould you be buying Bullfrog AI stock or one of its competitors? The main competitors of Bullfrog AI include Citius Oncology (CTOR), Assertio (ASRT), Telomir Pharmaceuticals (TELO), Viveon Health Acquisition (VHAQ), Ikena Oncology (IKNA), Skye Bioscience (SKYE), ImmuCell (ICCC), Seres Therapeutics (MCRB), Achilles Therapeutics (ACHL), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry. Bullfrog AI vs. Citius Oncology Assertio Telomir Pharmaceuticals Viveon Health Acquisition Ikena Oncology Skye Bioscience ImmuCell Seres Therapeutics Achilles Therapeutics Acumen Pharmaceuticals Citius Oncology (NASDAQ:CTOR) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment. Does the media prefer CTOR or BFRG? In the previous week, Citius Oncology had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 3 mentions for Citius Oncology and 2 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 0.99 beat Citius Oncology's score of 0.30 indicating that Bullfrog AI is being referred to more favorably in the news media. Company Overall Sentiment Citius Oncology Neutral Bullfrog AI Positive Is CTOR or BFRG more profitable? Citius Oncology's return on equity of -43.67% beat Bullfrog AI's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -43.67% -9.74% Bullfrog AI N/A -141.39%-124.63% Which has higher earnings & valuation, CTOR or BFRG? Bullfrog AI has higher revenue and earnings than Citius Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/A-$21.15MN/AN/ABullfrog AI$60K298.14-$5.36M-$0.81-2.35 Do analysts rate CTOR or BFRG? Citius Oncology presently has a consensus price target of $3.00, indicating a potential upside of 134.38%. Given Citius Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than Bullfrog AI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in CTOR or BFRG? Citius Oncology received 1 more outperform votes than Bullfrog AI when rated by MarketBeat users. Likewise, 33.33% of users gave Citius Oncology an outperform vote while only 0.00% of users gave Bullfrog AI an outperform vote. CompanyUnderperformOutperformCitius OncologyOutperform Votes133.33% Underperform Votes266.67% Bullfrog AIOutperform VotesNo VotesUnderperform Votes1100.00% Do institutionals and insiders hold more shares of CTOR or BFRG? 70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 4.6% of Citius Oncology shares are owned by company insiders. Comparatively, 33.9% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, CTOR or BFRG? Citius Oncology has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. SummaryCitius Oncology beats Bullfrog AI on 8 of the 13 factors compared between the two stocks. Get Bullfrog AI News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRG vs. The Competition Export to ExcelMetricBullfrog AIPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.89M$6.83B$5.57B$8.66BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-2.248.7927.2020.17Price / Sales298.14263.51412.92161.90Price / CashN/A65.8538.2534.64Price / Book4.426.677.114.72Net Income-$5.36M$143.49M$3.23B$247.80M7 Day Performance11.11%6.34%4.61%3.36%1 Month Performance7.95%15.43%13.35%9.71%1 Year Performance-29.63%6.87%31.75%14.41% Bullfrog AI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRGBullfrog AI1.6541 of 5 stars$1.90+11.1%N/A-35.0%$17.89M$60,000.00-2.244Positive NewsCTORCitius OncologyN/A$0.89-1.1%$3.00+237.0%N/A$63.69MN/A0.00N/ANews CoverageGap DownASRTAssertio1.4092 of 5 stars$0.66-1.2%$2.75+318.8%-33.6%$63.63M$119.00M-0.9020TELOTelomir Pharmaceuticals2.3523 of 5 stars$2.10+8.0%$15.00+614.3%-64.8%$62.50MN/A-3.621Gap UpVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeIKNAIkena Oncology2.7891 of 5 stars$1.28+7.6%$3.00+134.4%-16.0%$61.77M$659,000.00-1.0470SKYESkye Bioscience1.719 of 5 stars$2.25+29.8%$16.60+639.4%-78.5%$61.33MN/A-2.4411Analyst RevisionICCCImmuCell0.057 of 5 stars$6.78+5.9%N/A+43.0%$61.27M$27.30M-13.5670High Trading VolumeMCRBSeres Therapeutics3.0599 of 5 stars$7.00-0.7%$73.67+952.4%-33.6%$61.12M$126.33M-30.43330Positive NewsACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250ABOSAcumen Pharmaceuticals2.7979 of 5 stars$1.00-2.0%$7.33+633.3%-51.5%$60.57MN/A-0.7220Positive News Related Companies and Tools Related Companies Citius Oncology Competitors Assertio Competitors Telomir Pharmaceuticals Competitors Viveon Health Acquisition Competitors Ikena Oncology Competitors Skye Bioscience Competitors ImmuCell Competitors Seres Therapeutics Competitors Achilles Therapeutics Competitors Acumen Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRG) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bullfrog AI Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bullfrog AI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
